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Urinary tract infection (UTI) is a common disease and sometimes life threatening if not properly treated. In Nigeria, aside 
adulteration and counterfeiting of antibiotics, potency of antibiotics can also be altered by factors like production errors and 
storage condition at the Pharmacy stores. This study investigated the potencies of selected brands of four common parenteral 
antibiotic preparations, in Nigerian drug markets against uropathogens isolated from patients with recurrent UTI.  
 
Ten selected clinical bacterial isolates from patients with recurrent UTI were collected from the Microbiology unit of the 
University College Hospital, Ibadan and authenticated by standard bacteriological methods. The isolates were subjected to 
susceptibility test against eight standard antibiotics by disc diffusion method. The selected brands of the four parenteral 
antibiotic preparations used in this study includes: Ciprofloxacin (Emason® and Uniflox®); Ceftriaxone (Rocephin® and 
Cefin®); Aminoglycoside (Pe-genta® and Philo-genta®) and Aminopenicillin/inhibitor (Augmentin® and Amoxiclav®). 
Efficacies of the parenteral antibiotic preparations against the isolates were determined by Minimum Inhibitory Concentrations 
(MICs) using broth-dilution method.  
 
Antibiotic susceptibility test using standard antibiotic discs showed that all (100%) the bacterial isolates were multidrug 
resistant (MDR), being resistant to two or more classes of antibiotics. Aside E. coli (E1) that was susceptible to the two brands of 
gentamicin preparations at the Clinical Laboratory Standard Institute (CLSI) susceptibility breakpoint (≤ 4 µg/mL), all the other 
isolates showed resistance to the four parenteral antibiotic preparations and were only susceptible at higher concentrations (> 2 
folds) above the CLSI resistance breakpoints for the different antibiotic preparations. The brands of the parenteral antibiotic 
preparations used in this study have low potency which varies with different bacterial strains involved. 
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RESUME 
L’infection des voies urinaires (UTI) est une maladie commune et parfois met la vie en danger si pas correctement traitée. Au 
Nigeria, a part de la falsification et la contrefaçon des antibiotiques, la puissance des antibiotiques peut également être modifiée 
par des facteurs tels que les erreurs de production et les conditions de stockage dans les magasins de la pharmacie. Cette étude a 
examiné les puissances des marques sélectionnées de quatre préparations antibiotiques parentérales courantes, aux marchés 
nigérians de la drogue, contre les uropathogenes isolées des patients avec infection urinaire récidivante. 




Dix isolats bactériens sélectionnés des patients avec infection urinaire(UTI) récidivante ont été recueillies de l’unité 
microbiologie de l’hôpital Universitaire, Ibadan et authentifie par des méthodes bactériologiques classiques. Les isolats ont été 
soumis  à des tests de sensibilité contre huit antibiotiques Standards par la méthode de diffusion sur disques. Les marques 
sélectionnées de quatre préparations antibiotiques parentérales utilisées dans cette étude comprennent : Ciprofloxacine 
(Emason® et Uniflox®) ; Ceftriaxone (Rocephine® et Cefin®) ; Aminoside (Pe - genta® et Philo – genta®) ; et 
Aminopenicilline/inhibiteur (Augmentin® et Amoxiclav®). L’efficace des préparations antibiotiques parentérales contre les 
isolats ont été déterminés par concentrations minimales inhibitrices(MICs) en utilisant la méthode du bouillon – dilution. 
Le test de sensibilité aux antibiotiques en utilisant les disques antibiotiques standard a montré que tous (100%) les isolats 
bactériens étaient multi résistants (MDR), étant résistant aux deux ou plusieurs classes d’antibiotiques. A part de E.coli (E1) qui 
était sensible aux deux marques de préparations gentamicine a l’Institut de Laboratoire Clinique Standard. Le point d’arrêt de la 
sensibilité (≤ 4µg/ml) tous les autres isolats ont montré résistance aux quatre préparations antibiotiques parentérales et étaient 
seulement sensibles a des concentrations plus élevées (> 2 plis) au- dessus des points d’arrêt de résistance CLSI pour les 
préparations antibiotiques différentes. Les marques des préparations antibiotiques parentérales utilisées dans cette étude  ont 
une faible puissance qui varie avec les souches bactériennes différentes impliquées. 
INTRODUCTION 
Urinary system is classified into Lower (urethra, 
bladder) and upper (kidneys, renal pelvis) urinary 
tract, and the infection of the urinary system is when 
any one or all parts of the urinary system are infected 
by microorganisms, mostly bacteria, with significant 
bacteriuria in the presence of symptoms (1). Urinary 
tract infection (UTI) is described based on the location 
of the infection in the urinary system as either lower 
urinary tract infection (LUTI) or upper urinary tract 
infection (UUTI). Usually, someone is declared to 
have urinary tract infection (UTI) only if repeated 
viable count of the microorganisms in the urine 
samples of the person concern is ≥ 105 CFUmL-1 of the 
urine (1).  
Urinary tract infection caused by bacterial isolates is 
of global concern and the major setback in its 
treatment using antibiotic is the emergent of highly 
resistant bacterial strains (2, 3). Common bacterial 
isolates usually involved in UTI, either uncomplicated 
or complicated, are Escherichia coli, which is the most 
common, Klebsiella pneumoniae, Enterococcus faecalis, 
Streptococcus saprophyticus, species of Enterobacter, 
Serratia, Acinetobacter, and Pseudomonas aeruginosa (3, 
4, 5, 6). Aside the first line antibiotics such as 
trimethoprim-sulphamethoxazole, penicillins and 
nitrofurantoin, which are now obsolete in the 
treatment of UTI due to high level of resistance (7, 8), 
three major classes of antibiotics commonly used as 
second line treatment of UTI are the 
fluoroquinolones, aminoglycosides and some beta-
lactams (9). Resistance to these classes of antibiotics 
have been reported world-wide including Nigeria by 
several authors in their laboratory screening of 
clinical uropathogens and has contributed immensely 
to the problems encountered by physicians in the 
treatment of UTI (10, 11). Taken of antibiotics for too 
short a time, at an inadequate concentration, or for the 
wrong treatment, all constitute irrational use of 
antibiotics and thus contribute to the development of 
resistance among clinical bacterial isolates (2, 12, 13). 
Another issue of major concern is the use of 
antibiotics as growth promoters in food-producing 
animals and poultry flocks (14). Such practices have 
contributed to the rise in the level of antibiotic 
resistance and dissemination of resistance traits 
among microorganisms which in turns can be 
transmitted from animals to humans (15, 16, 17, 18).  
This study however, evaluated the potencies of two 
brands each, of fluoroquinolone (ciprofloxacin), 
aminoglycoside (gentamicin), cephalosporin 
(ceftriaxone) and amino-penicillin/inhibitor 
combination (amoxicillin-clavulanic acid) obtained 
from local pharmaceutical market in Ibadan against 
selected multidrug resistant uropathogenic bacterial 
isolates from patients diagnosed with recurrent UTI. 
 
MATERIALS AND METHODS 
COLLECTION OF UROPATHOGENIC 
MICROORGANISMS 
Ten bacteria isolated from ten patients with recurrent 
urinary tract infection were collected from the 
Microbiology and Parasitology Department of the 
University College Hospital (UCH), Ibadan on sterile 
nutrient agar slants and were authenticated by 
standard bacteriological techniques. Pure cultures of 
the authenticated bacterial isolates were sub-cultured 
on fresh nutrient agar slants and stored in the 
refrigerator at 4ºC. The bacterial isolates include two 
strains each of Pseudomonas aeruginosa (Ps1 & Ps2), 
Staphylococcus aureus (S1 & S2), Proteus spp (Pr1 & 
Pr2), Klebsiella spp (K1 & K2), and Escherichia coli (E1 & 
E2). 
 
SUSCEPTIBILITY TEST USING STANDARD 
ANTIBIOTIC DISCS 
Antibiotic sensitivity testing was carried out by the 
disc diffusion method on Mueller Hinton agar using 
the following selected standard antibiotic discs: 
amoxicillin-Clavulanic acid (AMC)- 20/10 µg, 
cefuroxime (CRX)- 30 µg, cefixime (CXM)- 5 µg, 
ceftazidime (CAZ)- 30 µg, gentamicin (GEN)- 10 µg, 
ofloxacin (OFX) - 5 µg, ciprofloxacin (CPR)- 5 µg, 
nitrofurantoin (NIT)- 300 µg. Pure colonies of each 
test organism were inoculated into tubes containing 
10ml of sterile nutrient broth and incubated at 37ºC 




for 24hrs. Thereafter, a 10-2 dilution of the stock 
bacterial suspension was made and a sterile cotton 
swab was used to evenly inoculate the entire dried 
surface of previously prepared and set Mueller 
Hinton agar plates. The selected standard antibiotic 
discs were firmly placed on the set agar plates using 
sterilized forceps. The agar plates were left for about 
30 minutes for effective diffusion of the antibiotics 
before being incubated at 37ºC for 24 hours. The 
diameters of the zone of growth inhibition were 
measured to the nearest millimetre and the results 
interpreted as sensitive or resistant based on the 
Clinical and Laboratory Standard Institute (CLSI) 
2011 guideline (19). 
 
MINIMUM INHIBITORY CONCENTRATION 
(MIC) DETERMINATION OF THE SELECTED 
PARENTERAL ANTIBIOTIC PREPARATIONS 
 
The parenteral antibiotic preparations used in this 
study include: Aminoglycoside (gentamicin inj: Philo-
genta® and Pe-genta®), Floroquinolone (ciprofloxacin 
inj: Uniflox® and Emason®), Cephalosporins 
(ceftriaxone inj: Rocephin® and Cefin®) and Amino-
penicillin (amoxicillin-clavulanic acid: Augmentin® 
and Amoxiclav®). These antibiotics were bought from 
reputable pharmaceutical stores located within 
Ibadan. 
Stock preparations of the antibiotic under 
investigation were diluted serially with nutrient broth 
such that the concentration was halved in each 
container in a series to give ten concentrations. This 
was done by adding 5ml of the solution of the test 
antibiotic aseptically to 5ml of double strength 
medium and mixed by shaking. With a fresh pipette, 
5ml of the mixture was transferred aseptically to the 
second tube which contains 5ml single strength 
medium. This was also mixed by shaking and the 
procedure repeated until the last tube giving the 
following concentrations: 256, 128, 64, 32, 16, 8, 4, 2, 1 
and 0.5µg/mL. Thereafter, 0.1ml of a 10-2 dilution of 
the overnight broth culture was added to each tube. A 
tube containing sterile broth only served as a control. 
The tubes were incubated at 37oC for 24 hours and the 
minimum inhibitory concentrations (MICs) of the 
different parenteral antibiotics preparations were 
determined and result tabulated.  
 
RESULTS 
The microbiological characterisation of the isolates 
confirmed their identities to be: Escherichia coli, 
Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas 
aeruginosa, and Staphylococcus aureus (Table 1). The 
results of the antibiotic susceptibility test using 
standard antibiotic discs shows that 90% of them 
were resistant to cefixime, cefuroxime, and 
ceftazidime. Percentage resistance to nitrofuratoin 
and ofloxacin was 70%, Gentamicin was 60% while 
for ciprofloxacin it was 20%. Seven (70%) of the 
isolates showed resistance to three classes of 
antibiotics while K2 and Pr2 each showed resistance 
to five and four classes respectively (Table 1). The 
results of the susceptibility test using different 
concentrations of the parenteral antibiotics are shown 
in table 2. All the isolates showed resistance to the 
four parenteral antibiotic preparations giving MIC 
values greater than the Clinical Laboratory Standard 
Institute (CLSI) guideline Resistance breakpoints for 
each antibiotic except against E. coli (E1) that was 
susceptible to the two brands of gentamicin 
preparations at 4µg/mL which was within CLSI 
susceptibility breakpoint of ≤4µg/mL. However, 
variations in potency exist among some of the 
different brands of antibiotics used in this study 
against the clinical isolates. The MIC of Uniflox® 
brand (4µg/mL) of ciprofloxacin against Pseudomonas 
earuginosa -Ps1 was reduced fourfold compared to 
that of Emason® brand (16µg/mL) as well as between 
Pe-gena® brand (64µg/mL) of Gentamicin and Philo-
genta® brand (256µg/mL) against Ps1. Also, MIC of 
Uniflox® brand (64µg/mL) against Klebsiella 
pneumoniae K1 was increased fourfold compared to 
the Emason® brand (16µg/mL). This also occurred 
between Augmentin® brand (64µg/mL) of 
amoxicillin-clavulanic acid and Amoxiclav® brand 














TABLE 1: ANTIBIOTIC RESISTANCE PROFILES OF THE UROPATHOGENS TO THE STANDARD ANTIBIOTIC DISCS 
Isolate ID Antibiotic Resistance Profile                                            No. of Antibiotic classes 
E1 
 




































AMC, NIT, GEN, CRX, CXM, CAZ, OFX 
5 
ID = Identity; E1& E2 = Escherichia coli, S1& S2 = Staphylococcus aureus; Ps1& Ps2 = Pseudomonas aeruginosa; Pr1& Pr2 = 
Proteus mirabilis; K1& K2 = Klebsiella pneumoniae, AMC = amoxicillin-Clavulanic acid; CRX = cefuroxime; CXM = cefixime; 
CAZ = ceftazidime; GEN = gentamicin; OFX = ofloxacin; CPR = ciprofloxacin; NIT = nitrofurantoin. 
TABLE 2: DETERMINATION OF MINIMUM INHIBITORY CONCENTRATIONS (MICs) OF PARENTERAL ANTIBIOTIC PREPARATIONS 
BY BROTH-DILUTION 
Isolate ID 
Brands of Ciprofloxacin 
CLSI BP = ≥ 4µg/mL 
Brands of Ceftriaxone 
CLSI BP = ≥ 4µg/mL 
Brands of 
Amoxicillin/clavulanic acid 
CLSI BP = ≥ 32/16µg/mL 
Brands of Gentamicin 
























































































































E1 4 4 > 256 > 256 256 256 4 4 
E2 128 128 > 256 > 256 256 256 256 > 256 
PS1 16 4 64 64 > 256 > 256 256 64 
PS2 16 16 64 64 > 256 > 256 64 64 
Pr1 8 8 64 64 128 256 64 64 
Pr2 128 128 256 256 256 256 > 256 > 256 
K1 16 64 > 256 > 256 256 256 > 256 > 256 
K2 128 128 > 256 > 256 256 256 > 256 > 256 
S1 16 16 64 64 64 256 > 256 > 256 
S2 128 128 128 128 > 256 > 256 > 256 > 256 
ID = Identity; E1& E2 = Escherichia coli, S1& S2 = Staphylococcus aureus; Ps1& Ps2 = Pseudomonas aeruginosa; Pr1& Pr2 = 
Proteus mirabilis; K1& K2 = Klebsiella pneumoniae, CLSI BP = Clinical Laboratory Standard Institute Breakpoint. 
DISCUSSION                                                        
Antibiotic resistance is a growing problem in the 
treatment of infections which has led to the 
narrowing of antibiotic options needed to treat 




bacterial infections thus making this problem a global 
concern and thus requiring global solution (2). 
Although the natural phenomenon by which 
resistance emerges is accelerated and amplified by a 
variety of factors, the most important cause is the 
inappropriate use of antimicrobial agents (15). With 
reference to the Clinical and Laboratory Standard 
Institute (CLSI), 2011 guidelines (19), the results 
obtained from the sensitivity test using standard 
antibiotic disc showed that all the bacterial isolates 
used in this study are multidrug resistant strains. This 
confirms the earlier report by Dada and Muili (2010) 
of wide spread of resistant uropathogens among 
patients with UTI in Ibadan, Southwest Nigeria (20).  
 
Variation observed in the potency of some brands of 
the parenteral antibiotics used in this study against 
the same organism could be as a result of differences 
in the formulation methods and excipients used 
which may affect the penetration of the antibiotics 
into the bacteria cell. Also, it could be as a result of 
the condition of storage which could affect product 
potency, efficacy and overall quality. The 80% 
susceptibility of the isolates to the standard 
ciprofloxacin disc and the 100% resistance of the 
isolates to the two brands of ciprofloxacin injection 
used in this study suggest that the potency and 
efficacy of the parenteral antibiotic preparations have 
been altered either during formulation or on shelf. 
Therefore, stringent regulations must be put in place 
to ensure that formulation and storage of antibiotics is 
done appropriately according to standard. In the 
preparation of parenteral antibiotics, care must be 
taken to ensure that current good manufacturing 
practices (CGMPs) are followed so as to produce 
drugs of high standard that will be physically and 
chemically stable throughout their intended shelf life. 
Packaging of drugs must maintain the products’ 
integrity throughout the shelf life and during 
administration. Agencies involved in the regulation of 
sales of drugs should make sure that pharmacies and 
chemists display and store their drug items under 
correct storage conditions without any compromise as 
poorly stored drugs can loss their efficacy and 
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